Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal can...
Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...
GSK Investigational Site, San Marcos, Texas, United States
Florida Cancer Specialists - North, Saint Petersburg, Florida, United States
Florida Cancer Specialists - South, Fort Myers, Florida, United States
Florida Cancer Specialists - East, West Palm Beach, Florida, United States
Levine Cancer Institute, Charlotte, North Carolina, United States
Sibley Memorial Hospital, Washington, District of Columbia, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
University of Florida, Gainesville, Florida, United States
University of Miami, Miami, Florida, United States
Orlando Health UF Health Cancer Center, Orlando, Florida, United States
Avera Cancer Institute, Sioux Falls, South Dakota, United States
CHU Saint-Pierre-Site Porte de Hal, Brussels, Belgium
IRCCS - Fondazione G. Pascale, Napoli, Italy
Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom
University of Chicago Medical Center, Chicago, Illinois, United States
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Tulane University, New Orleans, Louisiana, United States
Tom Baker Cancer Centre, Calgary, Alberta, Canada
London Regional Cancer Centre, London, Ontario, Canada
Juravinski Cancer Centre, Hamilton, Ontario, Canada
Meander medisch centrum, Amersfoort, Netherlands
Netherlands Cancer Institute, Amsterdam, Netherlands
Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.